GlassScriptPhysician profile
Vito A Brunetti
NPI 1336261056
$3,295.03
in general payments reported to CMS, 2019-2025
25 companies · $885 in 2025
The $885 reported for 2025 was more than what 77% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $100 · 2021: $160 · 2022: $469 · 2023: $703 · 2024: $812 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,400.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $908.74 | 2022-2025 | |
| Glaxosmithkline, LLC. | $432.84 | 2019-2025 | Nucala |
| Optinose US, INC. | $405.71 | 2019-2025 | |
| Aerin Medical INC. | $372.95 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $274.99 | 2019-2025 | Dupixent |
| Csl Behring | $210.56 | 2020-2025 | Haegarda, Andembry, Hizentra |
| Stryker Corporation | $98.96 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.82 | 2021-2024 | Cuvitru, Eohilia |
| Intersect Ent, INC. | $68.63 | 2020-2021 | |
| Inspire Medical Systems, INC. | $61.08 | 2024-2025 | Inspire |
| Alk-Abello, INC | $59.98 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Leo Pharma INC. | $44.97 | 2022 | |
| Merck Sharp & Dohme LLC | $36.38 | 2023 | Verquvo |
| Aimmune Therapeutics, INC. | $30.39 | 2022 | |
| Hikma Pharmaceuticals USA | $29.92 | 2023 | Ryaltris |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $29.87 | 2019 | |
| Medtronic, INC. | $26.14 | 2025 | Propel |
| Lilly USA, LLC | $19.64 | 2025 | Zepbound |
| Phathom Pharmaceuticals, INC. | $18.98 | 2025 | Voquezna |
| Phadia US INC. | $18.76 | 2022 | |
| Ionis Pharmaceuticals, INC. | $17.79 | 2025 | Dawnzera |
| Paratek Pharmaceuticals, INC. | $16.60 | 2025 | Xhance |
| Aytu Biopharma, INC. | $15.48 | 2025 | |
| Grifols USA, LLC | $14.35 | 2022 | |
| Pharming Healthcare, INC. | $12.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vito Brunetti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.